Company Announcement - No. 8/2018
Election of employee representative to Zealand's Board of Directors
Copenhagen, April 10, 2018 - Zealand Pharma A/S ("Zealand") announces that Jens Peter Stenvang has been re-elected as an employee representative on Zealand's Board of Directors.
Jens Peter Stenvang, Senior Application Specialist, has been employed at Zealand since 2010 and was first elected as an employee representative in 2014. He is appointed for a two-year term with effect from Zealand's Annual General Meeting 2018 on April 19, 2018. At the same time, Helle Haxgart, Accountant, will leave the Board of Directors.
From April 19, 2018, the employee-elected representatives on Zealand's Board are: Hanne Heidenheim Bak, Senior Project Director, and Jens Peter Stenvang, Senior Application Specialist. At the next election of employee representatives to the Board in 2020, all employee-elected board members will serve the same term.
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of proprietary medicines in late-stage clinical development focused on specialty gastrointestinal and metabolic diseases. In addition, Zealand has two marketed drugs under license to Sanofi and two compounds in clinical development under license to Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
